Abstract. Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. Despite progress in the diagnosis and treatment of HCC, prognosis remains unfavorable. Long non-coding RNAs (lncRNAs) are emerging as important factors in tumorigenesis and cancer progression; however, the underlying molecular mechanisms and clinical significance of lncRNAs in HCC remain largely unknown. The present study examined the expression pattern and clinical significance of a novel lncRNA, LOC728290, in HCC. Expression of LOC728290 was markedly decreased in HCC tissues compared with adjacent non-tumor liver tissues, as detected using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The area under the receiver operating characteristic curve for LOC728290 was 0.728. The expression of LOC728290 was associated with the level of α-fetoprotein and microvascular invasion. Furthermore, patients with low LOC728290 expression exhibited decreased recurrence-free survival times (P<0.05) compared with those with high LOC728290 expression. The results of the present study indicated that downregulation of LOC728290 in patients with HCC may be a powerful tumor biomarker, with potential clinical applications in prognosis as well as a therapeutic target.
Introduction
Hepatocellular carcinoma (HCC) is characterized by high morbidity and mortality, and is one of the most prevalent malignancies worldwide (1) . Although progress has been made in the diagnosis and treatment of HCC, the prognosis for patients with HCC remains poor due to resistance to conventional chemotherapy and radiotherapy (2, 3) . Following surgical treatment, >60% of patients experience recurrence and metastasis within 1 year (4). Biomarker-based tumor recognition has promise for condition assessments that guide treatment; however, currently, few biomarkers have been applied in clinical practice (5) . Therefore, it remains important to identify novel biomarkers for early diagnosis and prognosis evaluation for patients with HCC.
Long non-coding RNAs (lncRNAs) are >200 nucleotides in length and do not code for, but may interact with, proteins (6) . Although not as well-characterized as small non-coding RNAs, including microRNAs, lncRNAs serve important roles in the regulation of a variety of cellular processes, including stem cell pluripotency, cell growth, cell proliferation, apoptosis, metabolism and cancer cell migration (7) (8) (9) (10) (11) (12) . Functional lncRNAs may be useful in cancer diagnosis and prognosis and may serve as potential therapeutic targets. Tang et al (13) reported that three lncRNAs (RP11-160H22.5, XLOC_014172 and LOC149086) were upregulated in HCC relative to cancer-free controls. Furthermore, XLOC_014172 and LOC149086 were confirmed to be markedly increased in metastatic HCC. In addition, levels of these three lncRNAs were identified to be decreased following cancer resection in the majority of patients. Xu et al (14) identified an lncRNA, LALR1, that was involved in liver regeneration. Yuan et al (15) observed that lncRNA-activated by transforming growth factor b upregulation in HCC, modulated tumorigenesis and progression. Wang et al (16) identified that the oncofetal lncRNA PVT1 promoted proliferation and stem cell-like properties in HCC cells, suggesting that this lncRNA may be involved in HCC progression.
In the present study, microarray data from the human lncRNA datasets GSE55191 and GSE5804 were analyzed, and it was identified that lncRNA LOC728290 expression levels in HCC tissues were significantly decreased compared with adjacent non-tumor tissues (P<0.05). Distinct LOC728290 expression levels in HCC and paired adjacent non-tumor samples were then validated using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Furthermore, the association between LOC728290 expression Table I .
RNA preparation, reverse transcription and RT-qPCR. RNA from frozen HCC tissues and adjacent non-tumor tissues (n=65) was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's protocol. RNA integrity was evaluated using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.) and cDNA was synthesized from 50 ng total RNA for each sample. LOC728290 expression levels were quantified using RT-qPCR performed on an ABI 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using Maxima SYBR-Green RT-qPCR master mix (Thermo Fisher Scientific, Inc.), following the manufacturers' protocols. GAPDH expression was monitored as the endogenous control, and all samples were normalized to human GAPDH. All reactions were run in triplicate, using LOC728290-specific primers designed and synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). Primer sequences were as follows: LOC728290 5'-AAA GCA CAG GTG ACT GTA ACA C-3' (forward) and 5'-TGG GCA TTC TCA TCG CAG TC-3' (reverse), and GAP DH 5'-CAG CCT CAA GAT CAT CAG CA-3' (forward) and 5'-TGT GGT CAT GAG TCC TTC CA-3' (reverse). The amplification profile was 95˚C for 5 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and annealing at 60˚C for 30 sec. The median of triplicate reactions was used to calculate relative lncRNA expression (ΔCq=Cq median lncRNA-Cq median GAPDH). Expression fold changes were calculated using the 2 -ΔΔCq method (17) .
Statistical analysis. Statistically significant differences between groups were determined using two-tailed Student's t-tests. A receiver operating characteristic (ROC) curve was plotted to determine the discrimination of the expression level of LOC728290 discriminated between HCC tissues and adjacent non-tumor tissues. Associations between LOC728290 expression and clinicopathological characteristics were analyzed using one-way analysis of variance with Bonferroni correction. The association between RFS times and LOC728290 expression levels in patients with HCC was analyzed using Kaplan-Meier estimator analysis. All statistical analyses were performed using SPSS for Windows software (version 16.0; SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

lncRNA LOC728290 is downregulated in HCC tissues relative to adjacent non-tumor tissues.
To assess the potential clinical significance of LOC728290, the expression level in HCC tissues and adjacent non-tumor tissues was analyzed using RT-qPCR. LOC728290 expression was significantly downregulated in 83.0% of tumors (54/65; fold change ≥1.0), relative to adjacent non-tumor tissues (P<0.05; Fig. 1A and B) . A ROC analysis was performed to evaluate the ability of the LOC728290 expression to discriminate between the tumor and control samples. The total area under the curve (AUC) for LOC728290 was 0.728 ( Fig. 1C ), suggesting that the LOC728290 level has adequate sensitivity and specificity to discriminate between HCC tissues and adjacent non-tumor tissues.
lncRNA LOC728290 expression is associated with α-fetoprotein (AFP) levels and with microvascular invasion in patients with HCC.
To determine whether LOC728290 expression in HCC tissue was associated with clinicopathological parameters, AFP levels and the presence of microvascular invasion in samples from patients with HCC were examined. The AFP level is a critical tumor biomarker for patients with HCC. LOC728290 expression was decreased in tissue samples where serum AFP was ≥20 ng/ml ( Fig. 2A) . In addition, decreased LOC728290 expression was exhibited in patients with microvascular invasion compared with those without (Fig. 2B) .
Association between lncRNA LOC728290 expression and clinicopathological features of patients with HCC.
To further analyze the association between lncRNA expression and clinicopathological parameters, the 65 patients with HCC were divided into high-(n=32) and low-(n=33) LOC728290 expression groups, according to the mean value of LOC728290 expression in their tumor tissues. As presented in Table I , whereas the low-LOC728290 expression group exhibited increased serum AFP levels (P<0.05) and microvascular invasion (P<0.01) compared with the high-LOC728290 group, no significant association was identified between LOC728290 expression and other clinicopathological features including age, sex, tumor size, clinical stage, histological grade, alcohol consumption, smoking status, hepatitis B virus (HBV), recurrence, portal vein tumor thrombosis (PVTT) or liver cirrhosis.
LOC728290 expression is associated with RFS times in HCC.
Kaplan-Meier estimator and log-rank analyses were performed to examine the association between levels of LOC728290 expression and patient survival. As presented in Table II , LOC728290 expression, PVTT, tumor size and microvascular invasion were significantly associated with RFS times. In particular, patients with a low level of LOC728290 expression Table I . Association of long non-coding RNA LOC728290 expression with clinicopathological characteristics of patients with hepatocellular carcinoma. exhibited significantly decreased RFS times (P=0.023; Fig. 3 ) compared with patients with high LOC728290 expression. Significantly decreased RFS times were also observed in patients with PVTT (P<0.05), tumors ≥5 cm (P<0.001) or microvascular invasion (P<0.001). Thus, these data indicate that low expression of LOC728290 may indicate a poorer prognosis for patients with HCC.
LOC728290 expression ------------------------------------------------------
Discussion
HCC is one of the most common malignant tumors in China; its incidence and resulting mortality have increased annually (18) .
The mechanisms of occurrence and development of HCC are complex and involve altered activity of a number of oncogenes and tumor suppressor genes; abnormal expression of lncRNAs has been demonstrated to serve an important role in the processes of invasion and metastasis (19) (20) (21) . Previous studies have revealed that the lncRNAs H19, MALAT1 and HULC are important in HCC progression (22) (23) (24) ; however, only a limited number studies have addressed the biological function and clinical significance of lncRNAs in HCC.
In the present study, differential expression of a novel lncRNA, LOC728290, between HCC tissue and adjacent non-tumor tissues from patients with HCC was identified. Results demonstrated that LOC728290 expression in HCC was significantly decreased compared with non-tumor tissue. The ROC AUC of LOC728290 was 0.728, demonstrating specificity and sensitivity in the diagnosis of HCC. Patients with HCC with low levels of LOC728290 expression exhibited significantly decreased RFS times (P= 0.047) compared with patients with high expression. Furthermore, patients with HCC with PVTT (P<0.05), tumor size ≥5 cm (P<0.001) and microvascular invasion (P<0.001) exhibited significantly decreased RFS times (P<0.001), respectively, which initially revealed the prognostic value of LOC728290. Overall, LOC728290 may serve an important role in the development and progression of HCC.
It has been reported that aberrant lncRNA expression results in dysregulation of downstream effectors and that lncRNAs may serve essential roles in numerous biological functions leading to HCC, as lncRNAs including HOTAIR, H19 and ZEB1-AS1 have been identified to be potential prognostic indicators in a number of tumors (25) (26) (27) .
In the present study, the association between LOC728290 expression and clinicopathological characteristics of patients with HCC was analyzed and a significant negative association was revealed between LOC728290 expression and serum AFP levels. Determination of serum AFP levels is essential in the clinical diagnosis of liver cancer (28, 29) . Thus, the results of the present study led to the hypothesis that LOC728290 may be a promising biomarker for HCC. In addition, the results of the present study revealed that decreased LOC728290 expression was associated with microvascular invasion, which, along with PVTT, is a primary mechanism of extrahepatic metastasis in HCC (30, 31) . Results from the present study indicated that LOC728290 may serve an important role in the development of HCC and that an investigation of possible mechanisms is warranted. However, no significant association was revealed between LOC728290 expression and other clinicopathological features, including age, sex, tumor size, clinical stage, histological grade, alcohol consumption, smoking status, HBV infection, tumor recurrence, PVTT or liver cirrhosis. Much larger clinical cohorts and extended follow-up times are required to confirm the results of the present study. Further in vitro and in vivo experiments are required to investigate the function of lncRNA LOC728290 in HCC and to elucidate its role in the underlying molecular mechanisms of HCC onset and progression. To the best of our knowledge, the results of the present study identified for the first time that lncRNA LOC728290 levels were significantly decreased in HCC tissues and that downregulation of lncRNA LOC728290 was positively associated with increased serum AFP levels and microvascular invasion in patients with HCC. Patients with HCC with low levels of LOC728290 expression demonstrated significantly decreased RFS times compared with patients with higher expression. These results demonstrate that lncRNA LOC728290 may exhibit potential as a diagnostic and prognostic biomarker for HCC.
